Free Trial
NASDAQ:GNLX

Genelux 5/8/2025 Earnings Report

Genelux logo
$2.63 +0.21 (+8.68%)
Closing price 04:00 PM Eastern
Extended Trading
$2.68 +0.05 (+1.90%)
As of 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genelux EPS Results

Actual EPS
N/A
Consensus EPS
-$0.24
Beat/Miss
N/A
One Year Ago EPS
N/A

Genelux Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genelux Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Genelux Earnings Headlines

Benchmark Co. Remains a Buy on Genelux Corp. (GNLX)
Guggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX)
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Genelux reports FY24 EPS (95c), consensus (88c)
Genelux announces alignment with FDA of approval pathway for Olvi-Vec
See More Genelux Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genelux? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genelux and other key companies, straight to your email.

About Genelux

Genelux (NASDAQ:GNLX), a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

View Genelux Profile

More Earnings Resources from MarketBeat